Organisation
Laboratory for Disease Mechanisms in Cancer
Division
The Laboratory for Disease Mechanisms in Cancer conducts research into the link between the ribosome and cancer. The research questionson wich the laboratory focuses are:
1) What is the spectrum of acquired ribosome defects in cancer?
2) By what mechanisms do ribosome defects promote cancer?
3) Are ribosome defects therapeutically relevant?
Current researchers
1 - 10 of 12 results
- Kim De Keersmaecker (Responsible)
- Marino Caruso (Member)
- Kim De Keersmaecker (Member)
- Elien Heylen (Member)
- Xander Janssens (Member)
- Kim Kampen (Member)
- Grecia Marron Linares (Member)
- Daniele Pepe (Member)
- Linde Van Aerschot (Member)
- Daan Van den Bosch (Member)
Projects
1 - 10 of 42
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom4 Jul 2021 → TodayFunding: FWO fellowships
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → TodayFunding: BOF - scientific equipment program
- Role of -1 programmed ribosomal frameshifting dysregulation on the JAK2 oncogeneFrom25 Jul 2020 → TodayFunding: FWO fellowships
- Silent mutations in cancerFrom1 May 2020 → TodayFunding: H2020 - Frontier Research (ERC)
- The role of NKX2-1 in T-cell acute lymphoblastic leukemia and NKX2-1 cooperation with the ribosomal RPL10 R98S and NOTCH1 mutations.From1 Jan 2020 → TodayFunding: FWO research project
- Role of PTEN dysregulation downstream of ribosomal protein RPL5/RPL11 lesions in cancer.From1 Jan 2020 → TodayFunding: FWO research project
- Fidelity of translation in healthy agingFrom26 Sep 2019 → TodayFunding: BOF - doctoral mandates
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → TodayFunding: Foundations, funds and other with scientific goal
- Clonal evolution and biology of co-operative oncogenic events in acute lymphoblastic leukemia.From1 Oct 2018 → TodayFunding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 95
- Point-of-care therapeutic drug monitoring of adalimumab by integrating a FO-SPR biosensor in a self-powered microfluidic cartridge(2022)
Authors: Henry Ordutowski, Charlotte Van Tricht, Mattijs Bulcaen, Marta Ciwinska, Carolina Gutierrez Cisneros, Xander Janssens, Nick Geukens, Debby Thomas, Francesco Dal Dosso, Dragana Spasic, et al.
Number of pages: 9 - Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing(2022)
Authors: Sarah Meyers, Jolien De Bie, Lucienne Michaux, Nancy Boeckx, Anne Uyttebroeck, Kim De Keersmaecker, Johan Maertens, Heidi Segers, Jan Cools, Sofie Demeyer
Number of pages: 11 - Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping(2022)
Authors: Jolien De Bie, Sofie Demeyer, Jan Cools, Kim De Keersmaecker, Joris Vermeesch, Johan Maertens, Heidi Segers, Lucienne Michaux, Barbara Dewaele
Pages: 548 - 561Number of pages: 14 - Exploitation of the ribosomal protein L10 R98S mutation to enhance recombinant protein production in mammalian cells.(2022)
Authors: Benno Verbelen, Kim De Keersmaecker
Number of pages: 15 - Exploitation of the ribosomal protein L10 R98S mutation to enhance recombinant protein production in mammalian cells(2022)
Authors: Benno Verbelen, Paulien Verstraete, Sonia Cinque, Maya Imbrechts, Nick Geukens, Daniele Pepe, Kim Kampen, Kim De Keersmaecker
Pages: 100 - 114Number of pages: 15 - How Ribosomal Protein Mutations Translate Cancer(2021)
Authors: Stijn Vereecke, Kim De Keersmaecker
- 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia(2021)
Authors: Kim De Keersmaecker, Peter Vandenberghe, Stein Aerts, Jan Cools
Pages: 773 - 784Number of pages: 12 - CSYseq: The first Y-chromosome sequencing tool typing a large number of Y-SNPs and Y-STRs to unravel worldwide human population genetics.(2021)
Authors: Sofie Claerhout, Paulien Verstraete, Liesbeth Warnez, Simon Vanpaemel, Maarten Larmuseau, Ronny Decorte
Pages: e1009758 - PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia(2021)
Authors: Inge Govaerts, Charlien Vandersmissen, Johan Maertens, Nancy Boeckx, Kim De Keersmaecker, Heidi Segers, Jan Cools
Number of pages: 14 - Linking Serine/Glycine Metabolism to Radiotherapy Resistance(2021)
Authors: Kim Kampen
Number of pages: 25